The expression of the PI3K/AKT/mTOR pathway in gastric cancer and its role in gastric cancer prognosis

被引:60
|
作者
Ying, Jieer [1 ,2 ]
Xu, Qi [2 ]
Liu, Bixia [2 ]
Zhang, Gu [3 ]
Chen, Lei [2 ]
Pan, Hongming [1 ]
机构
[1] Zhejiang Univ, Coll Med, Sir Run Run Shaw Hosp, Dept Chemotherapy, Hangzhou 310016, Zhejiang, Peoples R China
[2] Zhejiang Canc Hosp, Dept Chemotherapy, Hangzhou, Zhejiang, Peoples R China
[3] Zhejiang Canc Hosp, Dept Pathol, Hangzhou, Zhejiang, Peoples R China
来源
ONCOTARGETS AND THERAPY | 2015年 / 8卷
关键词
gastric cancer; PI3K/AKT/mTOR; prognosis; MAMMALIAN TARGET; AKT INHIBITOR; MAPK PATHWAY; ACTIVATION; PREDICTS; MARKERS; MK-2206;
D O I
10.2147/OTT.S88592
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objective: To analyze the correlation between sequential aspects of the phosphoinositide- 3 kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway by immunohistochemistry in the primary lesion of gastric cancer, clinicopathologic factors, and survival in Chinese patients to explore the role of sequential analysis of multiple targets in prognoses. Methods: Immunohistochemistry was performed to examine the expression of PI3K, phosphorylated- AKT (p- AKT), and phosphorylated- mTOR (p- mTOR) in 59 primary lesion samples ranging from Stages I to IV after gastrectomy. The correlation between sequential expression of multiple targets, and clinicopathologic factors and survival was analyzed. Results: The positive expression rates of PI3K, p- AKT, and p- mTOR were 49%, 58%, and 56%, respectively. There were eleven cases with three biomarkers positive (19%), 22 cases with two biomarkers positive (37%), and 19 cases with only one biomarker positive (32%). Seven cases (12%) were all negative. Multi- factorial Cox regression analysis showed that neural invasion, vascular invasion, size of the tumor, lymph nodes affected, metastasis, carbohydrate antigen 19- 9 level, and PI3K/p- AKT/p- mTOR simultaneous expression were independent prognostic parameters. The risk of death for the cases with two biomarkers positive was 0.367 times that for the cases with three biomarkers positive (P=0.166). The risk of death for the cases with only one biomarker positive was 0.105 times that for the cases with three biomarkers positive (P=0.058). The risk of death for the cases with three biomarkers negative was 0.017 times that for the cases with three biomarkers positive (P=0.022). Conclusion: Our study generated the hypothesis that patients with gastric cancer with simultaneous expression of PI3K/p- AKT/p- mTOR had worse outcome. But we need more rigorous validation in a larger data set.
引用
收藏
页码:2427 / 2433
页数:7
相关论文
共 50 条
  • [11] The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma
    Matsuoka, Tasuku
    Yashiro, Masakazu
    CANCERS, 2014, 6 (03) : 1441 - 1463
  • [12] Targeting PI3K/AKT/mTOR and MAPK Signaling Pathways in Gastric Cancer
    Morgos, Diana-Theodora
    Stefani, Constantin
    Miricescu, Daniela
    Greabu, Maria
    Stanciu, Silviu
    Nica, Silvia
    Stanescu-Spinu, Iulia-Ioana
    Balan, Daniela Gabriela
    Balcangiu-Stroescu, Andra-Elena
    Coculescu, Elena-Claudia
    Georgescu, Dragos-Eugen
    Nica, Remus Iulian
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (03)
  • [13] KIRREL promotes the proliferation of gastric cancer cells and angiogenesis through the PI3K/AKT/mTOR pathway
    Wang, Tao
    Chen, Shuo
    Wang, Ziliang
    Li, Siyu
    Fei, Xichang
    Wang, Tong
    Zhang, Mingjun
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2024, 28 (01)
  • [14] LGR6 promotes the progression of gastric cancer through PI3K/AKT/mTOR pathway
    Ke, Jing
    Ma, Peng
    Chen, Jinpeng
    Qin, Jun
    Qian, Haixin
    ONCOTARGETS AND THERAPY, 2018, 11 : 3025 - 3033
  • [15] Rafoxanide promotes apoptosis and autophagy of gastric cancer cells by suppressing PI3K /Akt/mTOR pathway
    Liu, Jia-Zhou
    Hu, Yi-Lin
    Feng, Ying
    Guo, Yi-Bing
    Li, Yi-Fei
    Yang, Jun-Ling
    Mao, Qin-Sheng
    Xue, Wan-Jiang
    EXPERIMENTAL CELL RESEARCH, 2019, 385 (02)
  • [16] Diterpenoid tanshinones inhibit gastric cancer angiogenesis through the PI3K/Akt/mTOR signaling pathway
    Yu, Jie-ru
    Liu, Yu-yue
    Gao, Yang-yang
    Qian, Li-hui
    Qiu, Jia-lin
    Wang, Pei-pei
    Zhang, Guang-ji
    JOURNAL OF ETHNOPHARMACOLOGY, 2024, 324
  • [17] Clinicopathological significance of PI3K, Akt and survivin expression in gastric cancer
    Gu, Yongjuan
    Jin, Shidai
    Wang, Feng
    Hua, Yibin
    Yang, Li
    Shu, Yongqian
    Zhang, Zhihong
    Guo, Renhua
    BIOMEDICINE & PHARMACOTHERAPY, 2014, 68 (04) : 471 - 475
  • [18] PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?
    Peng, Yan
    Wang, Yuanyuan
    Zhou, Cheng
    Mei, Wuxuan
    Zeng, Changchun
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [19] Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
    Chen, Jiezhong
    Zhao, Kong-Nan
    Li, Rui
    Shao, Renfu
    Chen, Chen
    CURRENT MEDICINAL CHEMISTRY, 2014, 21 (26) : 3070 - 3080
  • [20] Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine
    Xie, Xia
    Tang, Bo
    Zhou, Jianyun
    Gao, Qing
    Zhang, Pengbing
    ONCOLOGY REPORTS, 2013, 30 (02) : 773 - 782